EHA 2023 | Feasibility of second CART19 administration with rituximab-based lymphodepletion in R/R B-ALL
Valentín Ortiz-Maldonado
• 8 Jun 2023
Valentín Ortiz-Maldonado, MD, Hospital Clinic de Barcelona, Barcelona, Spain, discusses the results of a study evaluating the feasibility of second CAR-T therapy administration in patients with B-cell acute lymphoblastic leukemia (B-ALL) with an adapted lymphodepletion regimen. The findings revealed that second CART19 infusion with prior rituximab-based lymphodepletion led to long-term remissions in a subset of patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
